Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A Phase III Open-Label, Long-Term Safety Study of Cevimeline Hydrochloride in Patients with Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region

M. S. Chambers, K. Hodge, J. Holland, C. Jones, R. Vitti, A.S. Garden, R.I. Haddad. A Phase III Open-Label, Long-Term Safety Study of Cevimeline Hydrochloride in Patients with Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region. ASTRO Meeting. 2006.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.